Eyenovia’s (EYEN) “Neutral” Rating Reaffirmed at LADENBURG THALM/SH SH

Eyenovia (NASDAQ:EYEN)‘s stock had its “neutral” rating reissued by analysts at LADENBURG THALM/SH SH in a research note issued to investors on Monday,Benzinga reports.

EYEN has been the subject of several other research reports. HC Wainwright downgraded Eyenovia from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $12.00 to $2.00 in a research note on Monday. Brookline Capital Management reaffirmed a “hold” rating on shares of Eyenovia in a research note on Friday, November 15th. Finally, William Blair reaffirmed a “market perform” rating on shares of Eyenovia in a research note on Friday, November 15th.

Eyenovia Stock Up 7.4 %

EYEN stock opened at $0.12 on Monday. The stock has a market capitalization of $7.64 million, a P/E ratio of -0.16 and a beta of 1.75. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.58. Eyenovia has a 12 month low of $0.09 and a 12 month high of $2.57. The firm has a 50-day moving average price of $0.47 and a 200-day moving average price of $0.70.

Eyenovia (NASDAQ:EYEN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same period in the previous year, the company earned ($0.18) earnings per share. As a group, equities research analysts anticipate that Eyenovia will post -0.5 EPS for the current fiscal year.

Insider Buying and Selling at Eyenovia

In other news, CEO Michael M. Rowe bought 50,000 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was acquired at an average price of $0.57 per share, with a total value of $28,500.00. Following the transaction, the chief executive officer now owns 82,927 shares of the company’s stock, valued at $47,268.39. This trade represents a 151.85 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 7.10% of the company’s stock.

Institutional Trading of Eyenovia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nations Financial Group Inc. IA ADV increased its position in Eyenovia by 24.4% during the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock valued at $30,000 after purchasing an additional 10,000 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Eyenovia during the 2nd quarter worth approximately $26,000. Ground Swell Capital LLC acquired a new stake in shares of Eyenovia during the 2nd quarter worth approximately $27,000. Financial Management Network Inc. acquired a new stake in shares of Eyenovia during the 3rd quarter worth approximately $39,000. Finally, SkyView Investment Advisors LLC acquired a new stake in shares of Eyenovia during the 2nd quarter worth approximately $87,000. Institutional investors and hedge funds own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.